Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06408246 · ClinicalTrials.gov registry record · Phase 2
ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression
A Phase 2 study of Depression, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
- 2
- Study locations
NCT06408246: Recruiting Phase 2 study of Depression, sponsored by Stanford University.
NCT06408246 is a Phase 2 study of Depression that is actively recruiting participants, run by Stanford University. The registered enrollment target is 162 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06408246, a Phase 2 study of Depression, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to understand how a psychotropic medication called guanfacine affects brain network functioning in humans, and how this function interacts with cognitive impairments in people experiencing depressive symptoms.
Primary Outcome
A score of \<=5 on the PHQ-9
Conditions Studied
Interventions
- DRUG Guanfacine
- DRUG Sertraline
Study Locations (2)
California
- Stanford Psychiatry and Behavioral Sciences Department - Palo Alto
Illinois
- University of Illinois at Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2026-03-03 |
| Est. Completion | 2029-02-01 |
| Phase | Phase 2 |
What NCT06408246 shows while recruiting
NCT06408246 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Guanfacine is the first listed.
NCT06408246 reports a single indexed study location in California, Illinois.
Frequently Asked Questions
What is clinical trial NCT06408246 about?
NCT06408246 is a clinical study titled "ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression". The purpose of this study is to understand how a psychotropic medication called guanfacine affects brain network functioning in humans, and how this function interacts with cognitive impairments in people experiencing depressive symptoms.
What is the current status of trial NCT06408246?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2026-03-03. Estimated completion is 2029-02-01.
What conditions does trial NCT06408246 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT06408246?
The interventions under investigation include: Guanfacine (DRUG), Sertraline (DRUG).
Who is sponsoring clinical trial NCT06408246?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06408246 being conducted?
This trial has 2 study locations across California, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06408246's enrollment target sits among peer trials
162 235th of 679 higher than 444 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy